A Retrospective Cohort Study to Evaluate the Rate of Good Responses to Lamivudine (LAM) Treatment in naive Chronic Hepatitis B (CHB) Patients With Certain Pre-treatment Characteristics.

Trial Profile

A Retrospective Cohort Study to Evaluate the Rate of Good Responses to Lamivudine (LAM) Treatment in naive Chronic Hepatitis B (CHB) Patients With Certain Pre-treatment Characteristics.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Lamivudine (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 May 2011 Actual end date changed from Jan 2011 to Apr 2011 as reported by ClinicalTrials.gov.
    • 11 Mar 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
    • 11 Mar 2011 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top